Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of organic compounds known as 6‑aminopurines. It features a purine core substituted at position 6 with an amino group and at positions 8 and 9 with a benzodioxole-methyl and butyl group respectively; it also contains a fluorine atom at position 2. The compound has been studied experimentally as an inhibitor of heat shock protein HSP90 (heat shock protein HSP90-alpha), which is involved in protein folding and stabilization under stress conditions. There are no approved indications or clinical uses for this molecule; it remains an experimental research tool in molecular chaperone biology.[1][2][10]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 8-(1,3-benzodioxol-5-ylmethyl)-9-butyl-2-fluoropurin-6-amine.